Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
HK Stock Market Move | Bilibili-W (09626) rises by over 5% again, with a cumulative increase of about 25% in the past six days. The new game "Three Kingdoms Baijiangpai" is scheduled for testing in October.
HK Stock Market Move | FLAT GLASS (06865) rose more than 3%. The price of photovoltaic glass in September was raised. Institutions expect further enhancement of profit margins for the company.
Guosen: Continue to be optimistic about the new product cycle in the gaming sector and pay attention to the opportunities in IP licensing and AI application layout.
HK Stock Market Move | Bilibili-W (09626) rises by over 5% again, with a cumulative increase of about 25% in the past six days. The new game "Three Kingdoms Baijiangpai" is scheduled for testing in October.
HK Stock Market Move | FLAT GLASS (06865) rose more than 3%. The price of photovoltaic glass in September was raised. Institutions expect further enhancement of profit margins for the company.
Guosen: Continue to be optimistic about the new product cycle in the gaming sector and pay attention to the opportunities in IP licensing and AI application layout.
